Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept add-on therapy for systemic sclerosis in clinical practice
ChiCTR2400085742Phase 4Completed
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Jun 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in systemic sclerosis (SSc), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoint: modified Rodnan skin score. Started Jun 2024; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2400085742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085742.